Kornimate/medical-research-clean huggingface dataset:
the effects of dexamethasone on the time to pain resolution in dental periapical abscess

Conditions: Dental Research; Pharmaceutical Preparations, Dental

Summary: an individual's quality of life can be seriously affected by the severity of dental pain. the emergency department is a common place to find those seeking relief from their dental pain- often times seeking removal of the affected tooth, dental anesthetic injections or oral pain medications. there are a number of dental infections that cause this type of debilitating pain. one such dental infection is termed periapical abscess. this infection involves the tooth pulp. these infections can arise in three ways: introduction through a defect in the enamel and dentin; from a periodontal pocket or an adjacent tooth; or hematogenous seeding of the pulp from mechanical irritation. as this disease process continues there are a number of complications including chronic pain and, more seriously, the spread of infection into deep spaces which can be a life threatening condition. the emergency department treatment of this infection includes pain control, antibiotics and dental referral for ultimate management of the infection. the purpose of our study is to investigate whether the addition of oral steroids will alter the time until patient experiences improvement in their dental pain. steroids are a commonly used anti-inflammatory that is used in the emergency departmentfor the purpose of pain relief from throat pain. as the pain from periapical infection is thought to be largely from the pressure we speculate that the anti-inflammatory effects of steroids may decrease the inflammation thus the pressure and may ultimately lead to a decrease in time until the patient experiences some relief from their pain.


Eligibility criteria:
inclusion criteria: patients included if they had clinical diagnosis of pulpitis/dental apical abscess and physical exam revealed pain with percussion of the affected tooth/teeth plus or minus evidence of periapical abscess (gingival erythema, swelling, draining pus). written informed consent was obtained from each patient prior to enrollment in the study.- exclusion criteria: 1. younger than 18 years old 2. immunosuppression : hiv patient, transplant patient, chemotherapy 3. history of diabetes 4. recent (\<1 month) or chronic steroid use 5. hospitalization required due to intractable vomiting/pain 6. pregnancy, self report
evaluate bacteriophage as a useful immunogen in patients with primary immune deficiency diseases (pidd)

Conditions: Primary Immune Deficiency Diseases

Summary: this protocol is designed to ascertain whether the bacteriophage 0x174 neoantigen is safe and effective as an antigen used in the evaluation of primary and secondary immune responses. bacteriophage 0x174 is given intravenously 2 billion pfu/kg of body weight; small blood specimens of 3-5 ml (about 1 teaspoon) are collected after 15 minutes, 7 days, 14 days, and 28 days. blood is collected at intervals following the administration of the bacteriophage and the number of phage/ml is determined by the agar overlay method using suspension of e. coli c and serially diluted patient's serum. phage-specific igg and igm are measured by neutralization assay. capacity of switch from igm to igg is determined.


Eligibility criteria:
inclusion criteria: 1. subject/parent or guardian willing to sign consent and adhere to study schedule 2. known or suspected primary immune deficiency exclusion criteria: 1. pregnancy 2. breastfeeding 3. unwilling to sign consent or adhere to study schedule 4. \ 85 yrs of age 5. previous reaction to vaccine

Keywords: pid pidd antibody deficiency cvid recurrent infections
study of the occurrence of cardiocirculatory arrest as a function of the level of hypoxemia during a maastricht 3 procedure

Conditions: Cardiac Arrest; Reanimation

Summary: evaluation of the level of hypoxemia during the occurrence of cardiocirculatory arrest during a maastricht iii organ donation procedure.

evaluation of the level of hypoxemia during the occurrence of cardiocirculatory arrest during a maastricht iii organ donation procedure.

Eligibility criteria:
for the donors : inclusion criteria : * patient over 18 years of age * organ donation procedure initiated in accordance with the legislation and procedures in force in france for the maastricht iii category * no opposition formulated by the relative to the patient's participation in the study exclusion criteria : * patient registered on the national register of refusals or living refusal of donation * pregnant or breast-feeding women * patients under guardianship, curatorship or legal protection * medical contraindication to organ donation according to the recommendations of the agence de biomédecine currently in force in france for the receiver inclusion criteria : * no opposition to the collection of data concerning him/her * patient over 18 at pre-transplant consultation * patient who has received an organ from a donor participating in the hephaistos protocol exclusion criteria : - patients under guardianship, curatorship or legal protection
delineation of target volume of stereotactic radiotherapy for spinal tumors

Conditions: Spinal Tumor

Summary: the purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.

the purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors. this is a bidirectional cohort study planned to enroll approximately 500 patients with metastatic spinal tumors. patients are divided into two groups according to the target delineation method. group 1：the target bolume only includes local tumor. group 2：the target bolume includes local tumor and adjacent vertebral area.

Eligibility criteria:
inclusion criteria: * patients with spinal metastases or primary tumors receiving stereotactic radiotherapy; * patients with sufficent pre-treatment imaging data * patients who can cooperate with imaging review and follow-up after radiotherapy. exclusion criteria: * patients with an expected survival of less than 3 months; * patients with second-course radiotherapy; * patients with physical conditions that cannot tolerate stereotactic radiotherapy; * patients with extensive spinal metastasis and no local therapeutic value
a health action process approach online intervention for people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to implement the person-centered internet-based health action process approach to promoting physical activity in people with multiple sclerosis (i.e., ehapa-ms online intervention) and assess the intervention's effectiveness and adherence.


Eligibility criteria:
inclusion criteria: * are 18 years old and above; * any type of multiple sclerosis * have not maintained 30 minutes of mvpa accumulated per day for 2 days of the week during the previous 6 months; * be relapse-free for the past 30 days; * show low risk for contraindications of physical activity indicated by no more than a single 'yes' response on the physical activity readiness questionnaire; * be able to walk with or without an assistive device; * are willing to be randomized to an intervention or control group, complete the surveys and questionnaires, and wear an accelerometer during the intervention period; * have a reliable internet access. exclusion criteria: * have a score \>14 for the leisure score index of the godin leisure-time exercise questionnaire; * no computer or mobile device access with the internet. * patient determined disease steps (pdds) score = 7 i.e., using a wheelchair or scooter most of the time, or pdds score = 8 being bedridden. * anyone living outside of the united states of america. * anyone who is unable to speak, read and write in english. * not willing to be randomized to an intervention or control group, complete the surveys and questionnaires, and wear an accelerometer during the intervention period.

Keywords: physical activity internet-based intervention
a phase iii study of jaktinib in adults with moderate and severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: a multicenter, randomized, double-blind, placebo-controlled phase iii clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis


Eligibility criteria:
inclusion criteria: * have fully understood the test and voluntarily signed the informed consent; * when signing the informed consent form, the age of male or female subjects must be ≥ 18 years old; * the onset time of atopic dermatitis was at least 1 year at the time of screening, and the subjects met the hanifin and rajka criteria for atopic dermatitis at the time of screening; * for women with reproductive ability and all male subjects, during the trial period and within 6 months after the discontinuation of the trial drug, they must maintain abstinence or contraception, including but not limited to physical and drug contraception. * the subjects were able to communicate well and agreed to follow the study and follow-up procedures. exclusion criteria: * the investigator considers that any subjects are not suitable to participate in the trial.
ultrasound-guided microendoscopic versus fluoroscopic-guided lumbar transforaminal epidural steroid injections

Conditions: Radiculopathy Lumbar; Disc Disease Lumbar

Summary: the purpose of this study is to compare the microendoscopic combined with ultrasound technique to the standard routinely used x-ray guided transforaminal steroid injection technique.

after being informed about the study and potential risks, all patients giving written informed consent will undergo screening to determine eligibility. patients who meet the eligibility criteria will be randomized in a double-blind manner to two groups. patients assigned to group a will undergo a fluoroscopy guided procedure while patients in group b will undergo a microendoscopic combined with ultrasound technique.

Eligibility criteria:
inclusion criteria: * age between 18 and 64 years old of either sex * disease status of american society of anesthesiologists grades i to ii * patients presenting with single-level disc disease and radiculopathy (l2-l3; l3-l4; l4-l5) for steroid injection * confirmation of herniated disk by ct or mri * able to give informed consent exclusion criteria: * age under 18 or over 64 years old * pregnant women * disease status of american society of anesthesiologists grades iii to iv * unable to provide an informed consent * radiculopathies at multiple spinal levels * non-lumbar herniated discs * clinically obvious or known spinal deformity or stenosis * previous spine surgery * local or systemic infection * allergy to steroids, anesthetics, or contrast material * uncorrectable coagulopathy and patients on anticoagulation therapy * patients who refuse the procedure * spine tuberculosis or tumors * prior injections within 3 months

Keywords: epidural injections lumbar manipulation fluoroscopy ultrasound
a relative bioavailability study between two formulations of sildenafil citrate

Conditions: Erectile Dysfunction

Summary: the purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.

bio-equivalence between two formulations of sildenafil citrate

Eligibility criteria:
inclusion criteria: * body mass index higher or equal to 18,5 and lower or equal than 29,9 kg/m2. * good health conditions or without significant disease, at medical discretion, according to the rules defined in the protocol, and evaluations undergone: clinical history, pulse and blood pressure measurements, physical and psychological examination, ecg and complementary laboratory examination. * able to understand the study nature and objective, including the risks and adverse effects and willing to cooperate with the investigator and act according to all the trial requirements, which is confirmed by signing the informed consent form. exclusion criteria: * hypersensitivity to the study drug or to the chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug. * history or presence of hepatic or gastrointestinal diseases, or other condition that affects the drug absorption, distribution, excretion or metabolism * history of hepatic, renal, lung, gastrointestinal, epileptic, hematological or psychiatric disease; hypo or hypertension of whatever etiology which demands treatment with drugs; history or occurrence of myocardial infarction, angina and/or cardiac failure;

Keywords: sildenafil bio-equivalence
effects of dry heat application for menstrual symptoms

Conditions: Reproductive Health

Summary: this randomized controlled trial was to determine the effect of dry heat applied on foot base of the 65 nursing students on menstrual symptoms and pain. a statistically significant difference was found between the three-day visual analog pain scale in both intervention and control groups. however, there was no difference between menstruation symptom scale subscale and total score avg of the intervention and control groups. applying hot pack to the sole of the foot can be expressed as an effective method to reduce pain. however, due to premenstrual syndrome is a complex process, the reduction of pain in the later days of the menstrual cycle in both groups can be psychological or be explained for physiological reasons.

the study was conducted as a randomized controlled trial, a non-blinded between 30 september 2019 and 29 november 2019. in the first stage of the present study, the premenstrual syndrome scale was used for all participants and the study was continued with the students with premenstrual syndrome symptoms based on the data acquired from the premenstrual syndrome scale. this stage was used only for restricting the sample group, rather than diagnosing or treating the students. in the second stage, the randomization of students included in the sample group was presented according to the consort diagram. the population of the study consisted of 452 female nursing students studying in the faculty of health sciences in a university. the students (n=75) who were absent in the school, took analgesics during the study, and did not agree to participate in the study, were excluded from the study. the students, who had no diagnosis of psychiatric disorder and history of endometriosis, stated that they menstruated regularly (between 22-35 days), did not use complementary and alternative treatments such as analgesics or massage throughout the study, had no diabetes or neuropathic problem causing nerve injury, did not take oral contraceptives, were over 18 years, and agreed to participate in the study, were included in the study.

Eligibility criteria:
inclusion criteria: * having no diagnosis of psychiatric disorder and history of endometriosis * stated that they menstruated regularly (between 22-35 days), * not use complementary and alternative treatments such as analgesics or massage throughout the study, * having no diabetes or neuropathic problem causing nerve injury, * not take oral contraceptives, * were over 18 years, * agreed to participate in the study exclusion criteria: * analgesics during the study * not agree to participate in the study

Keywords: menstruation hot pack application pain
music therapy for palliative care patients

Conditions: Palliative Care

Summary: this study aims to find out if music therapy is effective in improving the quality of life of palliative care patients. it will do this by comparing palliative care patients who receive music therapy with those who do not receive music therapy.

quality of life (qol) is very important for palliative care patients, and includes the physical, psychological, social, and spiritual aspects of a patient's life. music therapy is often used to help palliative care patients and there is some evidence that music therapy helps improve their quality of life, especially in relation to reducing levels of pain. many palliative care patients and their families have also said that music therapy is helpful. however, more research is needed to help healthcare providers and funders decide if music therapy really is a useful treatment for patients receiving palliative care.

Eligibility criteria:
inclusion criteria: only patients deemed able to engage with interactive music therapy will be invited to join the study. eligibility will be assessed by a clinician during inpatient admission using the eastern cooperative oncology group (ecog) scale and the abbreviated mental test (amt). * patients will be eligible if they have an ecog performance status of 0, 1, 2 or 3 (0 indicating the patient is asymptomatic, 1 the patient is symptomatic but fully ambulatory, 2 the patient is symptomatic and confined to bed for less than 50% of the day, and 3 the patient is symptomatic and confined to bed for more than 50% of the day)) indicating they are able to engage with interactive music therapy. - eligible patients will also have a score of 7 or more on the amt, indicating they are capable of providing meaningful informed consent and accurate responses to the study's primary outcome measurement tool. * patients with communication difficulties will also be eligible if they are able to indicate their responses to the questionnaire. * musical skills are not required. prior musical skills will not lead to exclusion from the study. the patient must freely consent to participation following receipt of information about the trial. exclusion criteria: * patients will be excluded from the study if they have an ecog performance status of 4 (4 indicating the patient is severely symptomatic and completely bedridden) or a score of 6 or less on the amt, indicating they may not be capable of providing fully informed consent or accurate responses to the study's primary outcome measurement tool. * participants who decide not to consent will be excluded from the trial. patients will be assured that this decision will have no implications for the care that they receive.
gliflozins and cardiovascular risk factors in type 2 diabetes (gioia)

Conditions: Type 2 Diabetes Mellitus

Summary: gioia represents a multicenter pragmatic prospective cohort study, aimed at evaluating the effects of sglt2 inhibitors currently marketed (dapagliflozin, canagliflozin, empagliflozin) on markers of vascular, myocardial and renal damage, in patients with type 2 diabetes not well controlled with metformin and/or basal insulin. the changes of the interest outcomes are compared with those obtained with a comparator glucose lowering class (dpp-4inhibitors) over a follow-up of two years.


Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least 5 years * new use of an sglt2-i or dpp4-i as add-on to metformin or insulin according to clinical practice * hba1c levels ≥ 7% and ≤ 8.5% * egfr ≥ 60 ml/min/1.73 m2 exclusion criteria: * type 1 diabetes or secondary diabetes resulting from specific causes * history of neurovascular ulcers * previous therapy with sglt-2i or dpp4-i in the 3 months prior to the study enrollment * history of cancer within the last 5 years * pregnancy or active breast-feeding * serum creatinine level ≥ 1.3 mg/dl in women and ≥ 1.4 mg/dl in men * egfr ≤ 60 ml/min/1.73 m2
subcutaneous vs. intramuscular testosterone

Conditions: Testosterone Deficiency; Hypogonadism, Male

Summary: in this randomized, cross-over study 20 subjects who are undergoing testosterone (t) therapy for the treatment of t deficiency will receive both subcutaneous testosterone therapy and intramuscular testosterone therapy. one group will receive a sq injection followed by an im injection and one group will receive an im injection followed by a sq injection. the primary objective of this study is to measure testosterone concentration in men after these two treatment routes and determine if there are any significant differences due to modes of administration. endpoints will include total serum testosterone and calculated free testosterone. a questionnaire will also be administered to assess overall patient experience with each route of administration.

subjects planning to initiate testosterone treatment via injection at mhb will be consented into the study. upon enrollment in the study, the randomization will be completed for each subject. blood collection will occur before each injection. subjects will rate pain on the likert scale following each injection. after treatment with the first mode of t administration (sq or im depending on randomization), subjects will come in for blood draws 3 days and 7 days following the injection. two weeks after the initial injection, subjects will come in for treatment with the second mode of t administration (sq or im depending on randomization). subjects will come in for blood draws 3 days and 7 days following the second injection. two weeks after the second injection, subjects will complete an end of study assessment with an investigator and will complete a survey assessing their satisfaction with treatment. subjects will likely continue testosterone therapy at men's health boston after completion of the study.

Eligibility criteria:
inclusion criteria: * ability to read, write, and understand english * age greater than or equal to 18 * diagnosed with testosterone deficiency * pre-enrollment testosterone concentration of less than 350 ng/dl * planning to initiate testosterone treatment at mhb * willing to be followed at mhb for at least one month * willing to provide informed consent for this study exclusion criteria: * previous exposure to exogenous t, clomiphene citrate, or other selective estrogen receptor modulators, unless off therapy for at least 12 weeks * american urological association prostate symptom score of 15 or greater or significant prostatic symptoms * history of carcinoma, tumors or induration of the prostate or the male mammary gland, including suspicion thereof * pre-enrollment serum psa more than 4 ng/ml * serious psychiatric disease or uncontrolled medical illness, as suspected from the history or clinical examination * used any sex hormones or steroidal anabolic drug supplements within 28 days before pre-enrollment testosterone collection or at any time throughout the study * incapable of giving informed consent or complying with the protocol